Cetrorelix inhalation

Drug Profile

Cetrorelix inhalation

Latest Information Update: 05 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sofotec
  • Developer AEterna Zentaris GmbH; Sofotec
  • Class Infertility therapies; Peptides
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 01 Aug 2006 No development reported for Benign prostatic hyperplasia in Germany (Inhalation)
  • 01 Jun 2004 AEterna Laboratories is now called AEterna Zentaris
  • 30 Dec 2002 Zentaris has been acquired by AEterna Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top